NCT02089230View on ClinicalTrials.gov

MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 27, 2014

Primary Completion Date

June 5, 2019

Study Completion Date

June 5, 2019

Conditions

Leukemia

Interventions

DRUG

MEK 162

"Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle.~Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston